The introduction of Retatrutide ZPHC, at a concentration of 120mg, is generating considerable excitement within the medical community. This innovative dual GIP and GLP-1 agonist medication appears to deliver notable improvements in body reduction compared to current therapies. Early patient data have demonstrated significant declines in body fat pe